AlveoGene

AlveoGene is an innovative biotech focused on transforming outcomes for patients with rare respiratory diseases through targeted, inhaled gene therapy. Its core asset is the InGenuiTy™ platform, a next-generation lentiviral vector system designed for high-efficiency transduction of lung epithelial cells, enabling durable expression and repeatable dosing. The company was formed in July 2023 by a consortium of leading UK life science investors and six world-renowned scientific founders from the UK Respiratory Gene Therapy Consortium, leveraging over £72 million in prior grant-funded research.

The InGenuiTy™ platform is a proprietary, next-generation lentiviral vector system specifically engineered for inhaled delivery to the lungs, enabling high-efficiency transduction of respiratory epithelium, durable transgene expression, and safe, repeatable administration.

AlveoGene competes with companies developing inhaled AAV gene therapies (e.g., 4DMT, Spirovant) and mRNA therapies for lung disease. Its main differentiation is the lentiviral platform's ability to be re-dosed safely, its large payload capacity, and its high efficiency of lung-specific transduction, validated by a partner's ongoing Phase 1 trial.